A study about the effects of the drug Vorinostat (Zolinza) in patients with a previously treated, recurring special form of uterine cancer (sarcoma).

Registry ID

EUCTR2016-000782-22

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Medical University of Graz

Start date

2017-01-03

Completion date

2019-02-04

Last update

2026-08-16

Conditions

• Uterine sarcoma

Summary

The main purpose is to test the efficacy of the hydroxamic acid-based HDAC inhibitor Vorinostat as monotherapy in patients with histone deacetylase-positive, progressive, metastatic uterine sarcomas after prior anti-proliferative therapy.

Locations

• , , Austria

View on source registry